Single User PDF
GBP 1499.00  

PDF 1-5 User License
GBP 2999.00  

PDF Site License
GBP 4999.00  

PDF Global Site License
GBP 6999.00  

UK Head Office
+44(0)1494 771930
USA
+(1) 508 861 0401
or Buy Now! online

Hot Reports:
The European Pharmaceutical Directory 2012 and The USA Pharmaceutical Directory 2012


International Directory of Biotechnology Companies 2012


USA Pharmaceutical Directory 2012


South and Central American Pharmaceutical Directory 2012


Pharmaceutical Directory of China 2012


Middle East Pharmaceutical Directory 2012


Indian Pharmaceutical Directory 2012


European Pharmaceutical Directory 2012

Table of Contents

Market Study
Published: July 2010
Pages: 130
Tables: 54
From: GBP 1499.00  Buy Now!
Research from: Visiongain
Sector: Corporate & Fiscal

– how will M&A affect the pharma industry this decade?

Last year was important for pharmaceutical mergers and acquisitions, with total deal values in 2009 reaching almost $150bn. Driving this activity were three ‘mega-mergers’ at the heart of the industry, as Pfizer took over Wyeth, Roche bought the remaining shares in Genentech, and Merck & Co acquired Schering-Plough. Those historic deals signal the continued importance of mergers and acquisitions (M&A) as a strategy among pharma companies, with associated benefits and challenges. The importance of consolidation and alliances will increase from 2010 onwards, as companies adapt to changing conditions within the industry and market. Companies will turn to M&A to consolidate their businesses and to diversify into other developmental areas, our new study discusses. How will recent M&A activity work out for the companies involved? Also, where will important M&A activities be most likely to occur during the remainder of this decade, and what will their prospects be? Our new report tackles questions such as those, providing analysis to aid your decision making and save you time.

Our report – Prospects for Pharma Mergers, Acquisitions and Alliances 2010-2020 – reviews the recent M&A history of the industry and determines which companies will be most likely to perform M&A, and which companies are most likely to be targeted. Our research shows that M&A activity will be important to the pharmaceutical industry from 2010 to 2020, with opportunities and challenges arising. Many companies will turn to mergers, acquisitions or alliances. But which deals will leave companies well placed to survive the patent cliff, consolidate operations and expand revenues? Our latest study tackles those questions.

Our study also reviews prominent companies operating in the pharma biotech sector, where big pharma companies will seek to expand their operations this decade. We assess R&D pipelines and existing products that have the potential to make a significant market impact. Our study covers the incentives to seek M&A deals and the difficulties that can arise from those transactions. In particular, our new report provides an overview of the options for companies seeking to increase R&D and commercial presence in the industry’s growth areas.

Comprehensive analysis of M&A for the pharmaceutical sector

Prospects for Pharma Mergers, Acquisitions and Alliances 2010-2020 critically examines that aspect of the pharmaceutical industry through a review of primary and secondary information sources. Our study provides revenue forecasts, market share analyses, discussions of products and strategies, as well as analyses of commercial drivers and restraints. There are 70 tables and figures included, as well as an expert interview. The result is a comprehensive market- and industry-centred study, with analyses and opinion to benefit your work.

Why you should buy Prospects for Pharma Mergers, Acquisitions and Alliances 2010-2020

This report gives you the following benefits in particular:
• You will find out the prospects for pharma M&A activity worldwide from 2010 to 2020, including predicted corporate strategies, likely acquisition targets and other information, quantitative and qualitative
• You will find out where the pharma sector is heading commercially from the present onwards, with analysis of the different ways in which companies will adapt to the changing conditions in the market and industry
• You will discover the prospects for leading companies and their corporate strategies from 2010 onwards
• You will receive revenue forecasts and other predictions, with supporting arguments and other information
• You will analyse important R&D activities and commercial prospects for leading products in the shifting pharma landscape, including revenue predictions
• You will identify key industry trends and best practice, with many examples and other supporting information, including original views and predictions
• You will discover the drivers, restraints, competition and opportunities influencing M&A activity in the pharma sector from 2010 onwards
• You will receive expert views from our survey.

You can obtain this report today

Our new study is essential reading for anybody interested in the global pharmaceutical industry and its corporate prospects from 2010 onwards. We predict that industry consolidation will become an increasingly attractive option, despite the costs and risks. R&D-based companies and the generics sector will be involved, with small-molecule and biologics producers standing to benefit, potentially, as well as some associated companies. Do you want to learn where, how and why? You can stay ahead by ordering our report today.

Companies Listed

Top of Page